Divisadero Street Capital Management LP Has $495,000 Stock Holdings in The Beauty Health Company (NASDAQ:SKIN)

Divisadero Street Capital Management LP reduced its stake in shares of The Beauty Health Company (NASDAQ:SKIN - Free Report) by 74.0% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 311,600 shares of the company's stock after selling 887,468 shares during the quarter. Divisadero Street Capital Management LP owned 0.25% of Beauty Health worth $495,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently made changes to their positions in SKIN. Bridgeway Capital Management LLC grew its position in Beauty Health by 13.6% during the 4th quarter. Bridgeway Capital Management LLC now owns 1,211,600 shares of the company's stock worth $1,926,000 after acquiring an additional 145,000 shares during the last quarter. BNP Paribas Financial Markets bought a new position in Beauty Health in the fourth quarter valued at about $129,000. Northern Trust Corp raised its holdings in Beauty Health by 6.8% during the 4th quarter. Northern Trust Corp now owns 663,752 shares of the company's stock worth $1,055,000 after purchasing an additional 42,078 shares during the last quarter. Price T Rowe Associates Inc. MD lifted its position in Beauty Health by 19.2% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 114,147 shares of the company's stock valued at $182,000 after purchasing an additional 18,400 shares during the period. Finally, Mirabella Financial Services LLP acquired a new position in Beauty Health during the 4th quarter valued at about $14,292,000. 93.26% of the stock is owned by institutional investors.

Beauty Health Trading Up 47.5 %

NASDAQ SKIN traded up $0.59 during trading on Friday, reaching $1.83. 6,475,875 shares of the stock traded hands, compared to its average volume of 1,083,786. The stock's 50-day moving average price is $1.18 and its 200 day moving average price is $1.45. The company has a quick ratio of 5.57, a current ratio of 6.56 and a debt-to-equity ratio of 9.23. The firm has a market cap of $229.14 million, a price-to-earnings ratio of -4.36 and a beta of 0.88. The Beauty Health Company has a fifty-two week low of $0.78 and a fifty-two week high of $3.59.

Beauty Health (NASDAQ:SKIN - Get Free Report) last released its quarterly earnings data on Thursday, May 8th. The company reported ($0.08) EPS for the quarter, beating analysts' consensus estimates of ($0.13) by $0.05. The business had revenue of $69.60 million during the quarter, compared to analysts' expectations of $63.88 million. Beauty Health had a negative net margin of 8.11% and a negative return on equity of 44.83%. Analysts predict that The Beauty Health Company will post -0.25 EPS for the current year.

Wall Street Analyst Weigh In

Separately, Canaccord Genuity Group reduced their price objective on shares of Beauty Health from $1.50 to $1.25 and set a "hold" rating on the stock in a research note on Monday. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating and one has assigned a buy rating to the stock. According to data from MarketBeat, the company has an average rating of "Hold" and a consensus target price of $2.45.

About Beauty Health

The Beauty Health Company designs, develops, manufactures, markets, and sells aesthetic technologies and products worldwide. The company's flagship product includes HydraFacial that enhance the skin to cleanse, extract, and hydrate the skin with proprietary solutions and serums. Its products also comprise Syndeo, a Delivery System designs to connects providers to the consumer's preferences to create a more personalized experience; consumables, such as single-use tips, solutions, and serums used to provide a hydrafacial treatment; SkinStylus SteriLock Microsystem, a microneedling device used for the treatment of enhancing appearance of surgical or traumatic hypertrophic scars on the abdomen and facial acne scarring in Fitzpatrick skin types I, II, and III; and Keravive, a treatment for scalp health.